中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

磷脂酰肌醇蛋白聚糖-3和甲胎蛋白联合检测对原发性肝癌的诊断价值

宋孟锜 杨永飞 王冬冬 由法平 陈立波

引用本文:
Citation:

磷脂酰肌醇蛋白聚糖-3和甲胎蛋白联合检测对原发性肝癌的诊断价值

基金项目: 

国家自然科学基金资助项目(30672067,30700190); 教育部新世纪优秀人才支持计划基金资助项目(NCET-07-318); 

详细信息
  • 中图分类号: R735.7

The diagnostic role of combination of glypican-3 and AFP in primary hepatic carcinoma

Research funding: 

 

  • 摘要: 目的通过联合检测磷脂酰肌醇蛋白聚糖-3(GPC3)、甲胎蛋白(AFP)在原发性肝癌患者血清及组织中的表达情况,探讨对原发性肝癌的诊断价值。方法分别采用ELISA和免疫组织化学法检测57例肝癌、74例肝炎后肝硬化患者和47例正常血清和肝组织GPC3、AFP表达水平,根据不同临床病理指标进行分组比较。结果 (1)肝癌患者、肝炎后肝硬化及正常对照者血清中GPC3水平分别为(212.6±137.5)、(60.9±27.8)、(39.5±18.7)ng/ml;肝癌患者血清GPC3浓度显著高于正常及肝炎后肝硬化患者(t=4.503,P<0.05;t=6.045,P<0.05);血清GPC3、AFP联合检测原发性肝癌的敏感性和特异性为84.2%和95.7%,均显著高于任一单项检测(t=4.132,P<0.05;t=6.514,P<0.05);(2)GPC3在肝癌组织表达高于癌旁和正常肝组织(t=3.724,P<0.05;t=15.799,P<0.05);GPC3与肿瘤大小、肿瘤数目、HBsAg及AFP水平无明显相关,而与病理分级和临床分期有关;(3)AFP阳性肝癌...

     

  • [1]Poon D, Anderson BO, Chen LT, et al.Management ofhepatocellular carcinoma in Asia:consensus statement fromthe Asian Oncology Summit 2009[J].Lancet Oncol, 2009, 10 (11) :1111-1118.
    [2]Marrero JA, Feng Z, Wang Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-boundalpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.
    [3]Capurro M, Filmus J.Glypican-3 as a serum marker forhepatocellular carcinoma[J].Cancer Res, 2005, 65 (1) :372-373.
    [4]毛伟征, 苏东明, 李雪萍, 等.AJCC癌症分期手册[M].沈阳:辽宁科学技术出版社, 2005:133.
    [5]申洪.免疫组织化学染色定量方法研究 (III) [J].中国组织化学与细胞化学杂志, 1995, 4 (1) :89-91.
    [6]De Cat B, David G.Developmental roles of the glypicans[J].Seminars in Cell&Developmental Biology, 2001, 12 (2) :117-125.
    [7]Llovet JM, Chen Y, Friedman SL, et al.A molecular signatureto discriminate dysplastic nodules from early hepatocellularcarcinoma in HCV cirrhosis[J].Gastroenterology, 2006, 131 (6) :1758-1767.
    [8]Nakatsura T, Yoshitake Y, Senju S, et al.Glypican-3, overexpressed specifically in human hepatocellularcarcinoma, is a novel tumor marker[J].Biochem BiophysRes Commun, 2003, 306 (1) :16-25.
    [9]Capurro M, Wanless IR, Sherman M, et al.Glypican-3:Anovel serum and histochemical marker for hepatocellularcarcinoma[J].Gastroenterology, 2003, 125 (1) :89-97.
    [10]Hippo Y, Watanabe K, Wantanbe A, et al.Identificationof soluble NH2-terminal fragment of glypican-3 asa serological marker for early-stage hepatocellularcarcinoma[J].Cancer Res, 2004, 64 (7) :2418-2423.
    [11]Zhu ZW, Friess H, Wang L, et al.Enhanced glypican-3 expressiondifferentiates the majority of hepatocellular carcinomas frombenign hepatic disorders[J].Gut, 2001, 48 (4) :558-564.
    [12]Zhou XP, Wang HY, Yang GS, et al.Cloning and expressionof MXR7 gene in human HCC tissue[J].World JGastroenterol, 2000, 6 (1) :57-60.
    [13]Libbrecht L, Severi T, Cassiman D, et al.Glypican-3 expression distinguishes small hepatocellular carcinomas fromcirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules[J].Am J Surg Pathol, 2006, 30 (11) :1405-1411.
    [14]Shafizadeh N, Ferrell LD, Kakar S.Utility and limitations ofglypican-3 expression for the diagnosis of hepatocellularcarcinoma at both ends of the differentiation spectrum[J].Mod Pathol, 2008, 21 (8) :1011-1018.
    [15]Wang DS, Ding HG, Li Z, et al.The diagnostic value of combination with GPC3 and AFP in hepatocellular carcinomas[J].Zhonghua Jianyan Yixue Zazhi, 2007, 30 (10) :1169-1171.
    [16]Jia HL, Ye QH, Qin LX, et al.Gene expression profilingrev-eals potential biomarkers of human hepatocellularcarcinoma[J].Clin Cancer Res, 2007, 13 (4) :1133-1139.
    [17]王钰.原发性肝癌血清肿瘤标记物检测研究进展[J].吉林医学, 2010, 31 (7) :988-989.
  • 加载中
计量
  • 文章访问数:  4207
  • HTML全文浏览量:  13
  • PDF下载量:  1093
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-10-25
  • 出版日期:  2011-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回